Kinetoplastid membrane protein-11 (KMP-11)

Kinetoplastid membrane protein-11 (KMP-11) is a highly conserved 11-kDa membrane glycoprotein expressed across all life stages of kinetoplastid parasites, including Leishmania and Trypanosoma species [3, 4]. It plays a fundamental role in parasite biology by interacting with subpellicular microtubules to regulate the cytoskeleton and is essential for critical processes such as basal body segregation, flagellar attachment, and cytokinesis [8, 16]. Beyond its structural roles, KMP-11 serves as a significant virulence factor that modulates the host immune system, notably by inducing interleukin-10 (IL-10) production and suppressing nitric oxide synthesis in macrophages [2, 25]. Due to its high antigenicity and essentiality for parasite survival, KMP-11 is a primary target for the development of vaccines and immunotherapies, with candidates like the ChAd63-KH vaccine reaching clinical evaluation [18, 23]. While it is not the primary target of current small-molecule antileishmanials, docking studies suggest potential interactions with drugs like miltefosine and paromomycin, highlighting its potential as a multi-functional therapeutic target [22].

Other names

Lipophosphoglycan-associated proteinLPGAP11-kDa membrane proteinLPG-associated protein

KMP-11 is targeted primarily through immunotherapy, where it acts as a potent antigen to elicit a protective Th1-mediated immune response, including T-cell proliferation and IFN-gamma production [14, 18, 19]. Additionally, it is a theoretical target for small-molecule inhibition of parasite cytokinesis and cytoskeletal integrity [8, 16].